Study of PF-08052667 for Bladder Cancer
This study is looking at PF-08052667, a new medicine for non-muscle invasive bladder cancer. Researchers want to understand how PF-08052667 works alone or with other treatments like Bacillus Calmette Guerin (BCG) and sasanlimab. This type of bladder cancer hasn't spread to the bladder muscle but is likely to return or grow. You might be able to join if you are an adult with this type of bladder cancer, especially if your cancer has come back or didn't go away after standard treatments like BCG, or if you can't receive those treatments. The main goal is to see how safe these treatments are by tracking side effects and other changes in your body.
- Study design
- This study is for adults aged 18 and older with high-risk non-muscle invasive bladder cancer. It plans to enroll 294 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be followed for side effects and laboratory changes from the first day through 30-37 days after your last study treatment, for up to about 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
At a glance
Conditions
NCT07206225
Where you'd take part
This study runs at 68 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
64th Street Outpatient and Innovation Center
New York, New Yorkno site contact published
Recruiting
AUC Urologists, LLC
Myrtle Beach, South Carolinano site contact published
Recruiting
Baptist M&S Imaging (Medical Center)
San Antonio, Texasno site contact published
Recruiting
Biorepository and Precision Pathology Center (BRPC)
Durham, North Carolinano site contact published
Recruiting
Cancer Center Outpatient Building
Dallas, Texasno site contact published
Recruiting
Carolina Urologic Research Center, LLC
Myrtle Beach, South Carolinano site contact published
Recruiting
Coastal Eye Group
Myrtle Beach, South Carolinano site contact published
Recruiting
Duke Cancer Institute
Durham, North Carolinano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of participants with dose limiting toxicities (DLTs) in dose escalation in Part 1 and Part 2 participants onlyDay of first dose (Day 1) Up to 21 days
Any AE occurring during the DLT observation period that is attributed to PF-08052667 and not to the underlying disease or other causes is considered a DLT. DLT rate estimated based on data from DLT-evaluable participants during the DLT evaluation period.
- Number of participants with adverse events (AEs) in Part 1 and Part 2 participants onlyFrom the first day through 30-37 days after the last study treatment, up to approximately 2 years
AEs as characterized by type, frequency, severity (CTCAE v5.0), seriousness, and relatedness to study drug(s).
- Number of participants with laboratory abnormalities in Part 1 and Part 2 participants onlyFrom the first day through 30-37 days after the last study treatment, up to approximately 2 years
Laboratory abnormalities as characterized by type, frequency, severity
- Recurrence-free survival (RFS) in Part 3 participants onlyThrough end of study and up to approximately 2 years
RFS is defined as the time from the first dose until recurrence of high-grade disease, or death due to any cause, whichever occurs first
- Event-free survival (EFS) in Part 3 participants onlyThrough end of study and up to approximately 2 years
EFS is defined as the time from the first dose until the first occurrence of an EFS event including progressive disease, recurrence of high-grade disease, or death due to any cause, whichever occurs first